Elizabeth McNally, MD
Cardiovascular Disease · Chicago, ILNPI 1104988658
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $109,244 of the $118,805 with a category attached, or 92.0%. 8 manufacturers reported payments, led by Pfizer at 30.3% of the total. Reporting peaked in 2019 at $44,810 and has fallen 80.5% since, to $8,719 in 2023. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $2475.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$36K
- Vertex$25K
- Amgen$23K
- Astrazeneca AB$16K
- AstraZeneca$7K
- Janssen Research & Development, LLC$6K
- plus $5K from 2 others
What the payments were for
- Consulting fees$109,24492%
- Travel & lodging$8,9968%
- Food & beverage$5650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $35,966 |
| Vertex | 1 | $25,000 |
| Amgen | 14 | $22,616 |
| Astrazeneca AB | 13 | $16,180 |
| AstraZeneca | 3 | $7,435 |
| Janssen Research & Development, LLC | 3 | $6,300 |
| Astrazeneca UK Limited | 1 | $3,135 |
| Regeneron | 2 | $2,174 |
How this compares
$118,805 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 13 | $17,496 |
| Rosuvastatin Calcium | 39 | $843 |
| Metoprolol Succinate | 43 | $587 |
| Losartan Potassium | 31 | $277 |
| Carvedilol | 13 | $64 |
| Metoprolol Tartrate | 22 | $50 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chicago
- Sandeep NathanChicago$892K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
- Sanjiv ShahChicago$246K
- Raja MutharasanChicago$146K
- Nitasha SarswatChicago$140K
- Evan SteinChicago$121K
- Dan FintelChicago$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.